TrialClinical and experimental immunology2018

No augmentation of indoleamine 2,3-dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients.

S Bigenzahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.